Fonorucetam (Fonturacetam)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceFonorucetamFonorucetam
Similar drugsTo uncover
  • Slim Story Prof
    pills inwards 
    Teva Pharmaceutical Enterprises Co., Ltd.     Israel
  • Phenotropil®
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Fonorucetam
    pills inwards 
    Life Sainses OHCF     Russia
    • Dosage form: & nbsppills
    Composition:

    Composition per one tablet:

    Active substance:

    Fonorucetam

    50.00 mg

    100.00 mg

    Excipients:

    Povidone K-17

    7.60 mg

    15.20 mg

    Microcrystalline cellulose

    83.50 mg

    167.00 mg

    Sodium carboxymethyl starch

    7.55 mg

    15.10 mg

    Magnesium stearate

    1.35 mg

    2.70 mg
    Description:Round plain cylindrical tablets from white to white with yellowish a shade of color with a bevel for a dosage of 50 mg, with a facet and a risk for a dosage of 100 mg.
    Pharmacotherapeutic group:Nootropic remedy
    ATX: & nbsp

    N.06.B.X   Other psychostimulants and nootropic drugs

    Pharmacodynamics:

    A nootropic drug with a pronounced antiamnestic effect has a direct activating effect on the integrative activity of the brain, promotes memory consolidation, improves concentration and mental activity, facilitates the learning process, increases the speed of information transfer between hemispheres of the brain and the stability of brain tissue to hypoxia and toxic effects ,has anticonvulsant action and anxiolytic activity, regulates the processes of activation and inhibition of the central nervous system (CNS), improves mood.

    It has a positive effect on the metabolic processes and blood circulation of the brain, stimulates redox processes, increases the energy potential of the organism due to the utilization of glucose, improves the regional blood flow in the ischemic areas of the brain. Increases the content of noradrenaline, dopamine and serotonin in the brain, does not affect the level of GABA, does not bind to GABAA and GABAAT receptors, does not have a significant effect on the spontaneous bioelectrical activity of the brain.

    It has no effect on respiration and cardiovascular system, shows an unexpressed diuretic effect, has anorexigenic activity in course use.

    The stimulating effect is manifested in the ability to exert a moderately pronounced effect, manifested in regard to motor reactions, increased physical performance, marked antagonism to the catalepytic action of neuroleptics, and also the weakening of the expression of the hypnotics of ethanol and hexobarbital.

    Psychostimulating action prevails in the ideatorial sphere.

    Moderate psychostimulant effect of the drug is combined with anxiolytic activity, it improves mood, has some analgesic effect, increasing the threshold of pain sensitivity.

    Adaptogenic action is manifested in increasing the body's resistance to stress in conditions of excessive mental and physical stress, fatigue, hypokinesia and immobilization, at low temperatures.

    Against the background of taking the drug, there is an improvement in vision, which is manifested in an increase in the severity, brightness and fields of vision.

    Improves blood circulation of the lower extremities.

    Stimulates the production of antibodies in response to antigen administration, which indicates immunostimulating properties, but at the same time does not promote the development of immediate type hypersensitivity and does not change the allergic skin inflammatory reaction caused by the introduction of a foreign protein.

    With the course application does not develop drug dependence, tolerance, "withdrawal syndrome."

    The effect is manifested with a single dose, which is important when using the drug in extreme conditions.

    Does not have teratogenic, mutagenic, carcinogenic and embryotoxic properties. Has a low toxicity, the lethal dose in an acute experiment is 800 mg / kg.

    Pharmacokinetics:

    Quickly absorbed, penetrates into various organs and tissues, easily passes through blood-brain barrier.

    Absolute bioavailability when taken orally is 100%.

    Maximum concentration in the blood (TmOh) is achieved through 1 h, half-life (T1/2) - 3 - 5 hours.

    It is not metabolized in the body. Output is unchanged: approximately 40% - with urine and 60% - with bile and then.

    Indications:

    - Diseases of the central nervous system of various genesis, especially associated with vascular diseases and disorders of metabolic processes in the brain, intoxication (in particular, in posttraumatic states and chronic cerebrovascular insufficiency), accompanied by deterioration of intellectual and mnestic functions, decreased motor activity;

    - Neurotic conditions, manifested by lethargy, increased exhaustion, decreased psychomotor activity, impaired attention, memory impairment;

    - Violations of the learning process;

    - Psycho-organic syndromes, manifested by intellectual-mnestic disorders and apatiko-abulic phenomena, as well as flaccid states in schizophrenia;

    - Convulsive states;

    - Obesity (alimentary-constitutional genesis);

    - Prevention of hypoxia, increased resistance to stress, correction of the functional state of the organism in extreme conditions of professional activity in order to prevent the development of fatigue and to increase mental and physical performance, correction of daily biorhythm, inversion of the "sleep-wake" cycle;

    - Chronic alcoholism (with the aim of reducing the phenomena of asthenia, intellectual-mnestic disorders).

    Contraindications:

    - Individual intolerance;

    - Children under 18 years of age (safety and efficacy of the drug are not established).

    Carefully:

    Patients with severe organic lesions of the liver and kidneys, severe arterial hypertension, with severe atherosclerosis, previous panic attacks, acute psychotic conditions that occur with psychomotor agitation - due to the possibility of worsening anxiety, panic, hallucinations and delusions, as well as patients,prone to allergic reactions to nootropic drugs of the pyrrolidone group.

    Pregnancy and lactation:

    It should not be prescribed during pregnancy and breast-feeding due to lack of clinical research data.

    Dosing and Administration:

    Inside.

    Take immediately after eating. The dose and duration of treatment should be determined by the doctor. Doses vary depending on the characteristics of the patient's condition. The average single dose is 150 mg (100 to 250 mg); the average daily dose is 250 mg (200 to 300 mg). The maximum allowable dose is 750 mg / day. It is recommended to take a daily dose of up to 100 mg once a day in the morning, and more than 100 mg divided into 2 divided doses. The duration of treatment can vary from 2 weeks to 3 months, an average of 30 days. If necessary, the course can be repeated after 1 month.

    To improve performance - 100 - 200 mg once in the morning hours, for 2 pedel (for athletes - 3 days).

    The recommended duration of treatment for patients with alimentary-constitutional obesity is 30 to 60 days at a dose of 100 to 200 mg once a day (in the morning hours). It is not recommended to take the drug after 15 hours.

    Side effects:

    Insomnia (in case of taking the drug later than 15 hours). In some patients in the first 1 - 3 days of admission, psychomotor agitation, hyperemia of the skin, a sensation of warmth, an increase in blood pressure are possible.

    Overdose:

    There were no cases of overdose.

    Treatment: symptomatic therapy.

    Interaction:

    Fonotracetam can strengthen the effect of drugs that stimulate the central nervous system, antidepressants and nootropic drugs.

    The drug exhibits a pronounced antagonism to the catalepsy of neuroleptics, and also reduces the severity of the hypnotic effect of ethanol and hexobarbital.

    Special instructions:

    With excessive psychoemotional exhaustion in the background of stress and fatigue, chronic insomnia, a single dose of the drug in the first day can cause a sharp need for sleep. Such patients on an outpatient basis should be advised to begin the course of the drug on non-working days.

    Effect on the ability to drive transp. cf. and fur:Care should be taken when controlling vehicles and mechanisms, especially in the first days of admission, considering the possible occurrence of drowsiness (see "Special instructions").
    Form release / dosage:Tablets of 50 mg and 100 mg.
    Packaging:

    For 10 tablets in a planar cell package.

    By 1, 2. 3, 4 or 5 contour mesh packages together with instructions for use in a pack of cardboard.

    Storage conditions:

    In the dark place at a temperature of no higher than 30 ° C.

    Keep out of the reach of children.

    Shelf life:3 years. Do not use after the expiration date indicated on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-004616
    Date of registration:25.12.2017
    Expiration Date:25.12.2022
    The owner of the registration certificate:Life Sainses OHCFLife Sainses OHCF Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.01.2018
    Illustrated instructions
      Instructions
      Up